Literature DB >> 20482250

Circulating soluble CTLA4 (sCTLA4) is elevated in patients with breast cancer.

Nasrollah Erfani1, Mahbobeh Razmkhah, Abbas Ghaderi.   

Abstract

Soluble CTLA4 (sCTLA4) was assessed in sera of 43 new cases with breast cancer and 44 age- and sex-matched healthy individuals by enzyme-linked immunosorbent assay method. Associations of sCTLA4 levels with the six important CTLA4 Single Nucleotide Polymorphisms (SNPs) and with the resulted haplotypes were investigated. Results revealed significant concentration of sCTLA4 in patients with breast cancer (23.5 ± 14.96 versus 7.69 ± 4.04 ng/ml, p < .001). Patients' sCTLA4 concentration observed to be affected by the SNPs at positions +49 and +1822 and haplotype combination TACACA/TACGTG. These findings suggest that increased sCTLA4 may contribute in CTLA4-induced suppression of tumor immunity and provide explanations for the widely reported association of CTLA4 gene with cancer.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20482250     DOI： 10.3109/07357901003630934

Source DB:  PubMed          Journal:  Cancer Invest        ISSN： 0735-7907            Impact factor:   2.176


  9 in total

Review 1.  Soluble immune checkpoint molecules: Serum markers for cancer diagnosis and prognosis.

Authors:  Rituparna Chakrabarti; Bhavya Kapse; Gayatri Mukherjee
Journal:  Cancer Rep (Hoboken)       Date:  2019-02-07

Review 2.  Screening for Multiple Autoantibodies in Plasma of Patients with Breast Cancer.

Authors:  Lauren Bassaro; Stephen J Russell; Elzbieta Pastwa; Stella A Somiari; Richard I Somiari
Journal:  Cancer Genomics Proteomics       Date:  2017 Nov-Dec       Impact factor: 4.069

3.  Soluble cytotoxic T-lymphocyte-associated antigen 4 (sCTLA-4) as a potential biomarker for diagnosis and evaluation of the prognosis in Glioma.

Authors:  Jiajia Liu; Xiaoyi Tian; Yan Wang; Xixiong Kang; Wenqi Song
Journal:  BMC Immunol       Date:  2021-05-18       Impact factor: 3.615

4.  Cytotoxic T lymphocyte antigen 4 expression in human breast cancer: implications for prognosis.

Authors:  Haiming Yu; Junlan Yang; Shunchang Jiao; Ying Li; Wei Zhang; Jiandong Wang
Journal:  Cancer Immunol Immunother       Date:  2015-04-17       Impact factor: 6.968

Review 5.  Clinical Benefit from Ipilimumab Therapy in Melanoma Patients may be Associated with Serum CTLA4 Levels.

Authors:  Anna M Leung; Agnes Fermin Lee; Junko Ozao-Choy; Romela Irene Ramos; Omid Hamid; Steven J O'Day; Myung Shin-Sim; Donald L Morton; Mark B Faries; Peter A Sieling; Delphine J Lee
Journal:  Front Oncol       Date:  2014-05-16       Impact factor: 6.244

6.  Genome-Wide Comparison of the Target Genes of the Reactive Oxygen Species and Non-Reactive Oxygen Species Constituents of Cold Atmospheric Plasma in Cancer Cells.

Authors:  Hwee Won Ji; Heejoo Kim; Hyeon Woo Kim; Sung Hwan Yun; Jae Eun Park; Eun Ha Choi; Sun Jung Kim
Journal:  Cancers (Basel)       Date:  2020-09-16       Impact factor: 6.639

7.  Serum and Tissue Expression Levels of Leptin and Leptin Receptor Are Putative Markers of Specific Feline Mammary Carcinoma Subtypes.

Authors:  Andreia Gameiro; Catarina Nascimento; Ana Catarina Urbano; Jorge Correia; Fernando Ferreira
Journal:  Front Vet Sci       Date:  2021-02-10

8.  Expression of CTLA-4 and Foxp3 in peripheral blood T cells of patients with squamous cell laryngeal carcinoma.

Authors:  Katarzyna Starska; Ewa Forma; Iwona Lewy-Trenda; Jan Woś; Paweł Papież; Marcin Mochocki; Piotr Morawski; Renata Kopta; Magdalena Bryś
Journal:  Contemp Oncol (Pozn)       Date:  2013-10-07

9.  Identification of Four-Jointed Box 1 (FJX1)-Specific Peptides for Immunotherapy of Nasopharyngeal Carcinoma.

Authors:  San Jiun Chai; Yoke Yeow Yap; Yoke Ching Foo; Lee Fah Yap; Sathibalan Ponniah; Soo Hwang Teo; Sok Ching Cheong; Vyomesh Patel; Kue Peng Lim
Journal:  PLoS One       Date:  2015-11-04       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.